melagatran has been researched along with Arteriosclerosis, Coronary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frebelius, S; Grip, L; Linder, R; Swedenborg, J | 1 |
| Falk, E; Hansson, GK; Hemdahl, AL; Thorén, P | 1 |
| Al-Mousa, EN; Salam, AM | 1 |
1 review(s) available for melagatran and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials.
Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Glycine; Humans; Prodrugs; Stroke; Thrombin; Thromboembolism; Venous Thrombosis | 2004 |
2 other study(ies) available for melagatran and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
Topics: Amino Acid Chloromethyl Ketones; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Coagulants; Coronary Artery Disease; Fibrinopeptide A; Glycine; Hirudins; Humans; Peptide Fragments; Piperidines; Protein C; Thrombin | 2003 |
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Topics: Animals; Apolipoproteins E; Azetidines; Benzylamines; Biomarkers; Coronary Artery Disease; Coronary Thrombosis; Electrocardiography; Glycine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptors, LDL; Thrombin; Troponin T | 2004 |